madman
Super Moderator
Never heard about oral TU LOL!
In this episode of The Dr. Gabrielle Lyon Show, Dr. Lyon sits down with Shalin Shah, CEO of Marius Pharmaceuticals, to explore the science, benefits, and future of testosterone therapy. Shalin has been a driving force behind bringing Kyzatrex, an FDA-approved oral testosterone, to market—making testosterone therapy more accessible and effective for both men and women. From breaking down misconceptions to advocating for better access to hormone therapy, this conversation sheds light on how testosterone plays a crucial role in overall health and wellness.
This episode is a must-listen for anyone interested in health optimization, longevity, or understanding how testosterone therapy can impact overall quality of life.
Who is Shalin Shah?
Shalin Shah is a distinguished leader in the field of metabolic health, specializing in testosterone replacement therapy. As the Chief Executive Officer of Marius Pharmaceuticals, he was instrumental in the development and FDA approval of KYZATREX® (testosterone undecanoate) CIII Capsules, an oral testosterone treatment for adult men with low or no testosterone levels due to certain medical conditions.
With a global investment background, Shalin transitioned into healthcare with a mission to revolutionize the industry through metabolic health. His leadership at Marius Pharmaceuticals is marked by innovative strategies that prioritize consumer access and education. Under his guidance, KYZATREX has been launched via consumer-focused channels that include preeminent national healthcare institutions, private-equity backed medical practices, and national telemedicine platforms.
Shalin’s expertise extends beyond corporate leadership; he is an influential voice in longevity medicine and an advocate for reevaluating testosterone medication regulations. His efforts aim to reshape public perception and education on testosterone therapy and its significance for global health. He believes that oral testosterone replacement therapy has created a much-awaited paradigm shift which is critical for addressing the worldwide men’s (and women’s) health crisis, marked by declining testosterone levels and lower life expectancies. His message is that testosterone replacement therapy is not just about adding years to life, but also about adding life to years.
Chapters
00:00:00 - Introduction to Oral Testosterone Therapy
00:07:25 - Understanding Testosterone Misconceptions and Risks
00:14:48 - The Role of Testosterone in Metabolic Health
00:21:55 - Testosterone Therapy: Historical Context and Challenges
00:29:13 - Oral vs Injectable Testosterone: Benefits and Comparisons
00:36:39 - Testosterone's Impact on Metabolic Syndrome and Diabetes
00:44:05 - Exploring Testosterone Therapy for Women
00:51:23 - The Future of Testosterone Therapy and Research
00:58:40 - Addressing Barriers to Testosterone Access and Education
01:05:55 - Kyzatrex: A New Approach to Testosterone Delivery
01:13:13 - Global Interest and Future Directions for Kyzatrex
In this episode of The Dr. Gabrielle Lyon Show, Dr. Lyon sits down with Shalin Shah, CEO of Marius Pharmaceuticals, to explore the science, benefits, and future of testosterone therapy. Shalin has been a driving force behind bringing Kyzatrex, an FDA-approved oral testosterone, to market—making testosterone therapy more accessible and effective for both men and women. From breaking down misconceptions to advocating for better access to hormone therapy, this conversation sheds light on how testosterone plays a crucial role in overall health and wellness.
This episode is a must-listen for anyone interested in health optimization, longevity, or understanding how testosterone therapy can impact overall quality of life.
Who is Shalin Shah?
Shalin Shah is a distinguished leader in the field of metabolic health, specializing in testosterone replacement therapy. As the Chief Executive Officer of Marius Pharmaceuticals, he was instrumental in the development and FDA approval of KYZATREX® (testosterone undecanoate) CIII Capsules, an oral testosterone treatment for adult men with low or no testosterone levels due to certain medical conditions.
With a global investment background, Shalin transitioned into healthcare with a mission to revolutionize the industry through metabolic health. His leadership at Marius Pharmaceuticals is marked by innovative strategies that prioritize consumer access and education. Under his guidance, KYZATREX has been launched via consumer-focused channels that include preeminent national healthcare institutions, private-equity backed medical practices, and national telemedicine platforms.
Shalin’s expertise extends beyond corporate leadership; he is an influential voice in longevity medicine and an advocate for reevaluating testosterone medication regulations. His efforts aim to reshape public perception and education on testosterone therapy and its significance for global health. He believes that oral testosterone replacement therapy has created a much-awaited paradigm shift which is critical for addressing the worldwide men’s (and women’s) health crisis, marked by declining testosterone levels and lower life expectancies. His message is that testosterone replacement therapy is not just about adding years to life, but also about adding life to years.
Chapters
00:00:00 - Introduction to Oral Testosterone Therapy
00:07:25 - Understanding Testosterone Misconceptions and Risks
00:14:48 - The Role of Testosterone in Metabolic Health
00:21:55 - Testosterone Therapy: Historical Context and Challenges
00:29:13 - Oral vs Injectable Testosterone: Benefits and Comparisons
00:36:39 - Testosterone's Impact on Metabolic Syndrome and Diabetes
00:44:05 - Exploring Testosterone Therapy for Women
00:51:23 - The Future of Testosterone Therapy and Research
00:58:40 - Addressing Barriers to Testosterone Access and Education
01:05:55 - Kyzatrex: A New Approach to Testosterone Delivery
01:13:13 - Global Interest and Future Directions for Kyzatrex
